RBC Bioscience Corporation (TPEX:6848)

Taiwan · Delayed Price · Currency is TWD

21.40

+0.10 (0.47%)

Oct 8, 2026, 11:53 AM CST

Market Cap	305.46M +18.2%
Revenue (ttm)	220.60M +9.3%
Net Income	21.06M +7.5%
EPS	1.47 +8.0%
Shares Out	14.27M
PE Ratio	14.55
Forward PE	n/a
Dividend	3.53 (16.52%)
Ex-Dividend Date	Sep 2, 2026

Volume	8,106
Open	21.30
Previous Close	21.30
Day's Range	20.65 - 21.40
52-Week Range	14.30 - 28.15
Beta	0.47
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About RBC Bioscience

RBC Bioscience Corporation manufactures and sells reagents and devices for life science and molecular diagnosis. It offers robotic bench-top workstation for nucleic acid purification under the MagCore Plus II and Giga Automated Nucleic Acid Extractor names; MagCore Super Automated Nucleic Acid Extractor, an automated workstation for nucleic acid extraction; and MagCore EDA Automatic Extraction and Smart PCR Setup, an instrument for nucleic acid extraction and PCR setup pre-treatment. The company also provides NGS, genomic DNA, viral nucleic aci... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1995

Employees 50

Stock Exchange Taipei Exchange

Ticker Symbol 6848

Full Company Profile

Financial Performance

In 2025, RBC Bioscience's revenue was 219.71 million, an increase of 7.05% compared to the previous year's 205.25 million. Earnings were 23.54 million, an increase of 9.17%.

Financial Statements